Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LZM012 in moderate to severe chronic plaque psoriasis
NCT06110676Phase 3Recruiting
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lzm012 in plaque psoriasis, sponsored by Livzon Pharmaceutical Group Inc.. Started Aug 2023; status: recruiting.
02
Drugs
lzm012
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06110676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110676.